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Abstract
Venous thromboembolism (VTE) is a common, heritable disease resulting in high rates of
hospitalization and mortality. Yet few associations between VTE and genetic variants, all in the
coagulation pathway, have been established. To identify additional genetic determinants of VTE,
we conducted a 2-stage genome-wide association study (GWAS) among individuals of European
ancestry in the extended CHARGE VTE consortium. The discovery GWAS comprised 1,618
incident VTE cases out of 44,499 participants from six community-based studies. Genotypes for
genome-wide single-nucleotide polymorphisms (SNPs) were imputed to ~2.5 million SNPs in
HapMap and association with VTE assessed using study-design appropriate regression methods.
Meta-analysis of these results identified two known loci, in F5 and ABO. Top 1,047 tag SNPs
(p≤0.0016) from the discovery GWAS were tested for association in an additional 3,231 cases and
3,536 controls from three case-control studies. In the combined data from these two stages,
additional genome-wide significant associations were observed on 4q35 at F11 (top SNP
rs4253399, intronic to F11) and on 4q28 at FGG (rs6536024, 9.7 kb from FGG) (p<5.0×10−13 for
both). The associations at the FGG locus were not completely explained by previously reported
variants. Loci at or near SUSD1 and OTUD7A showed borderline yet novel associations
(p<5.0×10-6) and constitute new candidate genes. In conclusion, this large GWAS replicated key
genetic associations in F5 and ABO, and confirmed the importance of F11 and FGG loci for VTE.
Future studies are warranted to better characterize the associations with F11 and FGG and to
replicate the new candidate associations.
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Venous thromboembolism (VTE), manifesting as either deep venous thromboembolism
(DVT) or pulmonary embolism (PE), is a common and clinically important cardiovascular
condition with a high mortality rate. Each year in the United States, approximately 2 million
adults develop DVT [Hirsh and Hoak 1996], and an estimated 600,000 PE hospitalizations
and 60,000 deaths occur [Anderson et al., 1991; Goldhaber 1994; Hirsh and Hoak 1996].
VTE constitutes the third most common life-threatening cardiovascular condition after
coronary heart disease (CHD) and stroke [Goldhaber 1994]. Twin and family studies suggest
that VTE is highly heritable, with heritability estimates ranging from 0.5 to 0.6 [Heit et al.,
2004; Larsen et al., 2003; Souto et al., 2000]. A growing number of genetic variants, most in
the coagulation and fibrinolysis pathways, have been consistently linked to VTE [Anderson
and Spencer 2003; Bezemer et al., 2008; Blondon et al., 2011; Cushman 2007; Dennis et al.,
2012; Emmerich et al., 2001; Germain et al., 2011; Heit et al., 2012; Lowe 2006; Rosendaal
1999a; Rosendaal 1999b; Smith et al., 2007; Tregouet et al., 2009]. New variants and
candidate genes may yet be identified by genome-wide investigations. In this study, we
conducted a two-stage investigation of 2.5 million single nucleotide polymorphisms (SNPs)
and their associations with risk of VTE among 9 epidemiologic studies that included 4,849
cases of European ancestry.
MATERIALS AND METHODS
Design
We conducted a two-stage GWAS that included discovery in 6 studies (CHARGE VTE),
examination of genome-wide significant and high-signal findings from the discovery
analysis in 3 independent populations, and testing of the high-signal markers in all 9 studies.
Each study was approved by the Institutional Review Board of its respective institution and
all participants provided informed consent.
Discovery: Study Population
The study sample for the discovery stage comprised 1,618 incident VTE cases among
44,499 participants from five cohort studies and one case-control study. The cohort studies
were the Longitudinal Investigation of Thromboembolism Etiology (LITE) [Cushman
2007], which consisted two population-based cohorts [Cushman 2007] (the Atherosclerosis
Risk in Communities (ARIC) Study [1989] and the Cardiovascular Health Study (CHS)
[Fried et al., 1991; Tell et al., 1993]), the Rotterdam Studies (RSI and RSII) [Hofman et al.,
2009], and the Women's Genome Health Study (WGHS) [Ridker et al., 2008]. The case-
control study was the Heart and Vascular Health (HVH) Study of Venous Thrombosis
[Smith et al., 2007].
All analyses in this study were restricted to participants of European ancestry (Table 1).
VTE Diagnosis
All VTE events were objectively-diagnosed DVT or PE that were confirmed by venous or
pulmonary imaging, pathology examination of thrombus removed at surgery, or autopsy
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(~5% of HVH cases were by physician diagnosis only). Among all events, each study
indentified idiopathic VTE events as those that had no obvious precipitants, such as major
surgery, major trauma, marked immobility, or cancer.
Further details on the study design and VTE ascertainment and classification are provided in
Supplementary Methods and Supplementary Table 1.
Discovery: Genotyping, Imputation and Quality Control (QC)
GWAS—Each study performed genotyping using genome-wide SNP arrays, and conducted
QC and imputation of the data to ~2.5 million autosomal SNPs identified in the HapMap II
sample of European ancestry (CEU). The SNP arrays were from Affymetrix or Illumina.
Before imputation, SNPs were filtered based on sample and SNP call rates, minor allele
frequencies (MAF), and Hardy-Weinberg equilibrium p-values. The imputation was
performed using MACH [Li et al., 2009b; Li et al., 2010] in ARIC, RSI, RSII, and WGHS,
and BIMBAM [Servin and Stephens 2007] in CHS and HVH. Details of the GWAS arrays
and genotyping, QC, and imputation are provided in Supplementary Methods and
Supplementary Table 1.
Discovery: Statistical Methods
Study-Specific Analysis—Each study conducted regression of VTE on genotype for
each SNP using additive genetic models. For cohort studies, Cox proportional-hazards
regression analyses were performed using allele dosages and times-to-event calculated from
cohort-entry to the time of first VTE diagnosis. Censoring occurred at time of death from
other causes, loss to follow-up, or the end of follow-up (2005 in ARIC, 2001 in CHS, 2009
in RS, and 2010 in WGHS). Analyses were adjusted for age, sex, and field center in ARIC,
age, sex, field center, and CHD status in CHS, age and sex in RS, and age and a single
eigenvector of ancestry in WGHS. Association analyses were conducted using the
ProbABEL package in ARIC, CHS, RS, and WGHS [Aulchenko et al., 2007]. In the HVH
case-control study, logistic regression implemented in R was used to assess the association
between allele dosage of each SNP and incident VTE while adjusting for study design
variables age, age by decade, hypertension status, menopausal status, and index year. Since
HVH uses incidence density sampling for the controls, under the assumption of proportional
hazards, which holds under the null hypothesis of independence between genotype and VTE
outcome, estimates of ORs in this study also estimate hazard ratios.
When associations were identified for loci previously shown to be associated with VTE, we
conducted secondary analyses that excluded carriers of known variants or conditioned on the
known variants to see if new, independent signals remained. These included the FV Leiden
causal variant (rs6025) and known variants in ABO and FGG. rs6025 was genotyped
separately from the GWAS in individual cohorts. Linkage disequilibrium (LD) statistics (r2)
were estimated from the HapMap CEU sample.
In secondary analyses, data were re-analyzed while restricting events to those that were
idiopathic.
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Meta-analysis—A fixed-effects meta-analysis with inverse-variance weighting was
performed to combine regression parameter (ie, beta: log hazard ratio or OR) and standard
error from the individual studies [Benjamin et al., 2009]. The following exclusion criteria
were applied to SNPs in each individual study before meta-analysis: 1) beta estimates > 5 or
< −5; 2) invalid standard error (NA or zero value); 3) imputation quality score (RSQ) ≤ 0.3;
and 4) post-meta-analysis population-size-weighted MAF < 0.024 (based on MAF*2* total
events <75) to remove SNPs for which standard error estimates are unreliable in survival
analysis [Strawderman 1997]. Prior to the meta-analysis, genomic control inflation factors
(λ) from individual GWAS were calculated and corrected for (when λ was greater than 1.0),
to account for population stratification. The λ from individual GWAS was around 1.00
(range: 0.94-1.06, Supplementary Table 1), suggesting negligible population stratification in
the individual studies. The meta-analysis yielded estimates of log risk ratio, standard error,
and p-value, along with an overall λ across all SNPs. The meta-analysis was performed
using METAL [Willer et al., 2010]. We used a conventional a priori threshold of genome-
wide significance of p< 5.0 × 10−8.
Investigation of GWAS Findings at the Second Stage
The investigation of top GWAS hits for VTE at the second stage was performed in three
case-control studies: the Mayo Clinic VTE Study (Mayo, US) [Heit et al., 2011], the
MARseille THrombosis Association VTE Study (MARTHA, France) [Germain et al.,
2011], and a French case-control study on early-onset VT (EOVT) [Tregouet et al., 2009].
The investigation in MARTHA and EOVT was by in silico analysis of existing data while
that in the Mayo study combined de novo genotyping with in silico analysis.
SNP selection—We identified SNPs in the discovery set that failed to reach genome-wide
significance but that nonetheless had p-values suggestive of an association with VTE. We
first used a p-value threshold of 0.001 to select the top tag SNPs and functional SNPs. These
were subsequently thinned to an “independent” set; independence being defined as an
r2<0.80 between the top SNP and adjacent SNPs from the same chromosome. This filter was
only applied to non-functional (intronic and intergenic) SNPs. A total of 939 tag SNPs were
selected. To fill the remaining capacity for the genotyping platform, the same tagging
procedure was applied to additional SNPs (with p>0.001) in order of their p-value. In total,
1,047 SNPs with p≤0.0016 were selected, of which 318 were available in silico from the
Mayo GWAS data and the remaining 729 were genotyped. The final set of 1,047 SNPs was
also submitted to the MARTHA and EOVT studies, where results were obtained using in
silico analysis.
De Novo Genotyping in Mayo—Genotyping was performed in 2,572 samples using the
Illumina Veracode platform by the Mayo Genotyping lab. Of the 729 genotyped SNPs, 30
were removed due to no call, missing call rate > 20% or being monomorphic. Forty-six
samples were removed due to ≥90% missing SNP calls.
Analysis of Genetic Associations with VTE—In Mayo, PLINK [Purcell et al., 2007]
was used to perform logistic regression to evaluate the association of the replication SNPs
with VTE adjusting for age and sex. In MARTHA and EOVT, logistic regression was
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conducted and adjusted for the first four principal components of ancestry, with PLINK
[Purcell et al., 2007] being used for genotyped SNPs and Mach2dat [Li et al., 2009b; Li et
al., 2010] for imputed ones.
Finally, for the 1,047 SNPs examined at the second stage, an inverse-variance weighted
meta-analysis was performed to combine association parameter from the discovery and
second-stage studies. To allow for the two-stage testing of the 1,047 SNPs in the meta-
analysis, we adjusted the significance threshold downward by a factor of two (p<2.5×10−8).
Heterogeneity of the association parameters across studies was assessed by Cochran's Q-
test[Willer et al., 2010].
RESULTS
GWAS Discovery
Manhattan and quantile-quantile (Q-Q) plots of p-value from the meta-analysis of the
discovery cohorts are shown in Figure 1 and Supplementary Figure 1, respectively. The
genomic inflation λ was 1.0009, consistent with negligible population stratification. A total
of 34 SNPs from two genomic regions exceeded the genome-wide significance threshold of
5×10−8: the F5/NME7 region at chromosome 1q24.2 (19 SNPs, spanning 379 kb) and the
ABO region at chromosome 9q34.1-q34.2 (15 SNPs, spanning 18 kb). Regional association
plots are shown in Figures 2 and 3.
The signals at the F5/NME7 region were led by an intronic variant rs2420370 and a coding
variant rs6427196 in the 3’ untranslated region of F5 (RR= 1.77 and 1.82 associated with
each copy of the minor G allele, Table 2). The FV Leiden variant (rs6025) was excluded
from the GWAS meta-analysis because of small MAF (<0.024) or poor imputation quality.
However, the significant signals at the F5 region disappeared after excluding approximately
5% of participants who were carriers of the FV Leiden variant that was genotyped separately
from the GWAS (smallest p>0.01, Supplementary Figure 2). The signals at the ABO region
were led by rs687621 (RR= 1.37, Table 2), an intronic variant in the ABO gene and a strong
tag for the O group: r2=0.67 with the O functional variant (rs8176719). Adjustment for
rs514659, one of the top SNPs for VTE and the strongest tags for O group (r2=0.71),
removed the associations for the remaining significant SNPs (smallest p > 0.01,
Supplementary Figure 3), consistent with the signals at this region being due to the effect of
the O blood group. The association of FV Leiden and ABO O variants with VTE is
established and therefore replication was not pursued [Anderson and Spencer 2003;
Bezemer et al., 2008; Blondon et al., 2011; Cushman 2007; Dennis et al., ; Emmerich et al.,
2001; Germain et al., ; Heit et al., 2012; Lowe 2006; Rosendaal 1999a; Rosendaal 1999b;
Tregouet et al., 2009].
The analyses for idiopathic VTE yielded similar results (Supplementary Table 2).
Meta-analysis of discovery and second-stage data for new discovery
In the meta-analysis that pooled data for the 1,047 replication SNPs from the discovery and
second-stage studies, two additional loci emerged at p< 2.5×10−8 at chromosomes 4q28
(seven SNPs in or around FGG) and 4q35 (two SNPs in or around F11). The signals at the
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FGG region were led by rs6536024 (RR=0.80, 95% confidence interval 0.76-0.85,
associated with each copy of minor allele), which is 9.7 kb downstream from FGG; it was
also the most significant SNP in the CHARGE cohorts (RR=0.79, 95% confidence interval
0.73-0.87). One of the significant SNPs (rs1049636, p=2.54×10−8 in all studies) is located at
the 3’ untranslated coding region of FGG. The signals at the F11 region were led by
rs4253399 (RR=1.24, 95% confidence interval 1.17-1.31), an intronic variant to F11 (Table
2). Regional association plots at the FGG and F11 regions are shown in Figures 4 and 5.
Using summary relative risks and allele frequencies from the meta-analysis, we estimated
sibling relative risks (λs) attributable to each of the lead variants in the ABO, F5, F11, and
FGG regions [Risch and Merikangas 1996]. Assuming a multiplicative model within and
between variants, these four variants together account for a λs of 1.11, below the sibling
relative risk estimate of 2.45 based on a nationwide register of hospitalizations in Sweden
[Zoller et al., 2011]. These results indicate that the established common variants included on
the GWAS arrays are largely insufficient to explain the heritability of VTE in populations of
European ancestry.
Additionally, five high-signal variants were identified in the second-stage meta-analysis at
p<1.0×10−5 and marked four novel chromosomal regions (Table 2). Two SNPs are from
sushi domain containing 1 (SUSD1); one is from ovarian tumor (OTU) domain containing
7A (OTUD7A); one is an intergenic SNP at chromosome 3p26 and about 90 kb from
contactin-6 (CNTN6); and one is an intergenic SNP on chromosome 5q13.3 that is about 6.1
kb from synaptic vesicle glycoprotein 2C (SV2C) (Table 2). Regional association plots at the
four loci are shown in Supplementary Figures 4-7.
Test of homogeneity across studies—For the genetic associations presented in Table
2, no significant heterogeneity was detected among the CHARGE cohorts (p>0.01). When
the CHARGE results were compared with the second-stage data, only the ABO variant
rs687621 showed a significant difference (p=1.5×10−5), with the risk estimates being higher
in the second-stage samples, especially in the two French studies.
DISCUSSION
We provided the results of a discovery GWAS for VTE including a total of 1,618 VTE cases
from 44,499 participants of European origin in six population-based studies. We further
investigated the associations for the top 1,047 SNPs identified from the GWAS in 3,231
VTE cases and 3,536 controls from one US and two French case-control studies. The
discovery GWAS confirmed the well-known associations of the FV Leiden variant and the
ABO O blood group [Rosendaal and Reitsma 2009; Tregouet et al., 2009]. The combined
analysis of the discovery and the second stage data identified additional genome-wide
significant signals at the FGG and F11 regions, in which variants were associated with 20%
reduced and 24% increased risk of VTE, respectively. Associations at these two loci have
been previously reported but not well characterized. Four subthreshold new associations
were within or close to the SUSD1, OTUD7A, CNTN6, and SV2C genes, identifying new
candidate loci for VTE and coagulation pathways.
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Only three GWAS studies have previously evaluated VTE, mainly involving hospital-based,
case-control samples [Germain et al., 2011; Heit et al., 2012; Tregouet et al., 2009]. These
three studies, two in French and one in the Mayo clinic populations, also provided
replication data here. In the first French and the Mayo GWAS, the only genome-wide
significant variants were those that were in high LD with the FV Leiden or in the ABO
region [Heit et al., 2012; Tregouet et al., 2009]. The second French GWAS included 1,542
VTE cases and 1,110 controls and pooled data with those from the first French GWAS
[Germain et al., 2011]. In the pooled analysis of the two French GWAS, variants in the F11
and FGG loci also reached genome-wide significance, with the top SNPs being two
intergenic variants rs3756008 and rs7659024 that are close to F11 (<2 kb) and FGG (<5 kb),
respectively.
FGG and F11
The FGG locus identified in this study may or may not reflect a different loci than those
reported by the French GWAS [Germain et al., 2011] and other candidate gene studies
[Carter et al., 2000; Grunbacher et al., 2007; Nowak-Gottl et al., 2009; Smith et al., 2007;
Uitte de Willige et al., 2005; Uitte de Willige et al., 2009]. In our CHARGE discovery
GWAS, the top FGG SNP rs6536024 is in modest LD (r2=0.18-0.26) with three tightly
linked FGG SNPs (rs7659024, rs2066865, rs2066854, r2=1.0 among them) and a FGA
polymorphism rs6050 (Thr312Ala, r2= 0.88 with rs2066865) identified in these studies
[Carter et al., 2000; Germain et al., 2011; Grunbacher et al., 2007; Smith et al., 2007; Uitte
de Willige et al., 2005; Uitte de Willige et al., 2009]. Of note, the minor allele of rs2066865
has been associated with reduced γ' fibrinogen levels which increased VTE risk [Uitte de
Willige et al., 2005]. These reported SNPs showed a weaker association with VTE in the
CHARGE cohorts than the top CHARGE SNP: rs7659024 (RR=1.16, p=1.2×10−3),
rs2066865 (RR=1.16, p=1.3×10−3), and rs6050 (RR=1.17, p=7.3 ×10−4) vs. rs6536024
(RR=0.79, p=4.0×10−7). In CHARGE, rs6536024 was also in LD with another FGG SNP
rs1049636 (r2=0.53; RR=0.86, p=9.6×10−4 for rs1049636 in CHARGE) that tagged a
different haplotype than rs2066865 and was associated with increased γ' fibrinogen levels
and lower risk of VTE in one of the candidate gene studies [Uitte de Willige et al., 2009]. In
CHARGE, the signal for rs6536024 was modestly reduced but not completely abolished
after adjustment for rs7659024 (p=4.1×10−4 for rs6536024) or rs1049636 (p=7.6×10−4).
Moreover, two FGG haplotypes defined by rs1049636 and two other SNPs rs2066861 and
rs2066860 were associated with DVT in a German family study of pediatric DVT [Nowak-
Gottl et al., 2009]. Notably, rs2066861 is tightly linked with rs2066865 (r2=1.0) while
rs2066860 was not associated with VTE in CHARGE (p=0.42). Therefore, we postulate that
the FGG locus identified in CHARGE either reflects a different locus than those tagged by
rs7659024 or rs1049636, or it is more tightly linked with the causal variant among the
haplotypes analyzed in the CHARGE meta-analysis.
The top F11 SNP rs4253399 identified in this study is in high LD with the top variant
rs3756008 from the pooled analysis of the two French GWAS (r2=0.91) [Germain et al.,
2011], indicating that they likely reflect the same underlying locus. Another two intronic
variants in F11, rs2036914 and rs2289252, were reported to be associated with the risk of
VTE in candidate gene studies [Li et al., 2009a; Smith et al., 2007]. More interestingly,
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these two variants were found to confer independent risk for VTE in one study [Li et al.,
2009a]. These two SNPs are closely correlated with our top F11 variant rs4253399: r2=0.78
and 0.53 with rs2289252 and rs2036914, respectively. Therefore, it is difficult to disentangle
the independence of VTE risk associated with the three variants based on the current data.
Subthreshold Associations—Of the four candidate loci that showed subthreshold
associations with VTE in this study, the most biologically compelling is SUSD1, which
encodes the sushi domain-containing protein 1 precursor. A typical sushi domain contains
approximately 60 amino acids and four cysteines [Ichinose et al., 1990] and is believed to
serve as a common motif in protein-protein interaction [Komaromi et al., 2011; Wei et al.,
2001]. This domain has been found in a number of proteins including factor XIII [Ichinose
et al., 1990; Ichinose et al., 1986; Komaromi et al., 2011]. The B-subunit of FXIII serves as
inhibitor of, and carrier for the potentially active A subunit and consists of 10 sushi domains,
which appeared to be involved in interaction and complex formation with FXIII-A
[Komaromi et al., 2011]. A His95Arg substitution in the sushi domains of FXIII-B was
associated with increased risk of VTE in two independent studies [Komanasin et al., 2005].
Therefore, we hypothesize that SUSD1 protein might interact with factors of the coagulation
pathway via the sushi domains to increase the risk of VTE. These suggestive associations for
VTE, if confirmed in other studies, raise the possibility of new candidate genes and
pathways for venous thrombosis.
Strengths and Limitations—The CHARGE GWAS represents a large population-based
GWAS study for VTE. While all of the genome-wide significant loci have been previously
reported, the population-based samples in CHARGE provide direct estimates of the VTE
risk these loci confer in the general population. In addition, our study adds to the literature
by confirming the importance of the F11 and FGG loci, which emerged in a few recent
studies and were not well characterized for VTE. The SNP arrays used in current GWAS
studies, including this one, are designed to capture common genetic variations based on the
HapMap data and thus may miss some additional common variants as well as low frequency
and rare variants. Imputation to the HapMap data provides an uniform panel for pooling data
of different SNP arrays but might be subject to measurement errors. To reduce the influence
of measurement errors, all SNPs with low imputation quality were excluded from the meta-
analysis. The residual measurement error introduced by imputation is not correlated with the
disease outcome and thus does not bias the results. It does, however, reduces statistical
power compared to measuring the full genotypes. The variants identified in FGG and F11 in
this and the previously published studies are either intronic or intergenic and do not appear
to influence protein structure and function. It is possible that the responsible variants in the
FGG and F11 loci are rare, functional variants that were not included on the genome array
or in the HapMap SNP panel and thus not imputed in our samples. For example, the recently
completed 1000 Genomes Project Data increased the number of variants in LD with
published GWAS signals by more than twofold when compared with the HapMap data
[Abecasis et al., 2012]. As such, the confirmation of FGG and F11 loci as important genes
for VTE should stimulate finemapping studies, such as those utilizing next-generation
sequencing technologies, to identify the underlying, responsible variants in these loci.
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In summary, in this large GWAS, we demonstrated at genome-wide significance level key
genetic associations for VTE in the general population, including with the F5, ABO, FGG,
and F11 loci. Our study also identified additional candidate loci that are not known to affect
coagulation or thrombosis. Future studies are warranted to identify the causal variants in
F11 and FGG regions and to replicate the new candidate associations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Manhattan plot showing the genome-wide −log10 p-values against physical position for total
incident VTE in CHARGE.
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Regional association plot for total incident VTE at the F5 region on chromosome 1 in
CHARGE. The horizontal line indicates the genome-wide significance threshold of
p=5.0×10−8. The top SNP is shown by blue triangle. The color of the remaining SNPs
reflects the r2 with the top SNP based on the HapMap CEU data with the following color
scheme: r2≥0.8 – red, 0.5 ≤ r2 < 0.8 - orange, 0.2 ≤ r2 < 0.5 - yellow, and r2 < 0.2 - white.
The light blue line represents the recombination rate (the y axis at right side) based on the
data from the HapMap CEU population. Gene annotations are shown under the x axis.
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Regional association plot for total incident VTE at the ABO region on chromosome 9 in
CHARGE.
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Regional association plot for total incident VTE at the FGG region on chromosome 4 in
CHARGE.
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Regional association plot for total incident VTE at the F11 region on chromosome 4 in
CHARGE.
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